|1.||Meng, Xiangyi: 26 articles (06/2015 - 01/2008)|
|2.||Lane, Roger: 20 articles (01/2010 - 01/2003)|
|3.||Farlow, Martin R: 17 articles (06/2015 - 09/2003)|
|4.||Grossberg, George T: 16 articles (07/2015 - 01/2002)|
|5.||Olin, Jason T: 14 articles (04/2011 - 06/2007)|
|6.||Tekin, Sibel: 12 articles (04/2011 - 12/2004)|
|7.||Koumaras, Barbara: 11 articles (04/2010 - 06/2003)|
|8.||Emre, Murat: 10 articles (01/2014 - 12/2004)|
|9.||Bullock, Roger: 10 articles (08/2010 - 03/2002)|
|10.||Cummings, Jeffrey L: 9 articles (01/2015 - 09/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
04/01/2015 - "The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study. "
07/01/2009 - "A randomized controlled trial (n = 541) showed that, compared with placebo, rivastigmine (mean, 8.6 mg/d) significantly improved scores on 2 coprimary cognitive outcome scales in PDD, including the Alzheimer disease Cooperative Study-Clinician's Global Impression of Change. "
04/01/2008 - "This study shows that long-term treatment with rivastigmine, at dosages approved for therapeutic use in Alzheimer's disease, produces significant improvement in all behavioral symptoms in 2 forms of VaD, MID and sVaD, except delusions. "
01/01/2015 - "Rivastigmine (6 to 12 mg daily orally or 9.5 mg daily transdermally) appears to be beneficial for people with mild to moderate Alzheimer's disease. "
03/01/2014 - "Because the cholinergic system is down-regulated in the brain of Alzheimer's disease patients, cognitive deficits in Alzheimer's disease patients are significantly improved by rivastigmine treatment. "
09/01/2006 - "The aim of the present study (a double-blind, placebo-controlled clinical trial) was to determine the utility of the Mattis dementia rating scale - the most commonly used scale in PD patients - to assess the efficacy of a 24-week rivastigmine treatment. "
09/01/2006 - "Compared with placebo, a 24-week rivastigmine treatment led to a significant improvement in the overall score on the Mattis dementia rating scale (p = 0.031), with a trend towards a significant improvement in the "Attention" subscale score (p = 0.061). "
01/01/2003 - "Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed dementia), and in patients with VaD. "
07/01/2012 - "Our study suggests that there are differences in the efficacy of Ginkgo biloba and rivastigmine in the treatment of Alzheimer's dementia. "
12/16/2000 - "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study."
|3.||Parkinson Disease (Parkinson's Disease)
06/01/2015 - "Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study."
01/01/2013 - "The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen."
11/01/2001 - "This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. "
05/01/2015 - "Cognitive, psychiatric, and motor symptoms were assessed before and after 24 weeks of treatment with rivastigmine using unstructured clinical assessments and rating scales including the Unified Parkinson's Disease Rating Scale, Mini-Mental State Examination (MMSE), and the Neuropsychiatric Inventory. "
01/01/2015 - "Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients."
|4.||Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
05/01/2005 - "Small open-label studies of patients with subcortical vascular dementia showed that rivastigmine improved attention, executive function, apathy and other behavioral deficits. "
01/01/2013 - " trial included 40 participants with subcortical vascular dementia (age range 40 to 90 years) with a mean mini-mental state examination (MMSE) score of 13.0 and 13.4 in the rivastigmine and placebo arms, respectively. "
09/01/2008 - "VantagE (Vascular Dementia trial studying Exelon) was a 24-week, multicentre, double-blind study. "
09/01/2008 - "Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study."
05/01/2005 - "Rivastigmine appears to be a promising agent in vascular dementia but its effects remain to be established in double-blind, placebo-controlled clinical trials."
|5.||Schizophrenia (Dementia Praecox)
11/01/2003 - "In conclusion, rivastigmine significantly improved quality of life in subjects with schizophrenia. "
07/01/2012 - "Thirty inpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia treated with ECT were coadministered rivastigmine (3-4.5 mg/d) or placebo in a prospective, randomized, double-blind, placebo-controlled trial (maximum period of 4 weeks). "
07/01/2006 - "The current study investigated the cognitive effects of Rivastigmine given as an add-on therapy to antipsychotic-treated schizophrenia patients in a placebo-controlled double-blind design. "
07/01/2006 - "This study investigated the effect of rivastigmine on memory in schizophrenia using event-related potentials (ERPs). "
07/01/2006 - "Studies have reported beneficial effects of cholinergic enhancers, e.g., rivastigmine, on memory in schizophrenia but others have not. "
|3.||Cholinesterase Inhibitors (Anticholinesterases)
|9.||Ginkgo biloba extract 761 (Rokan)
|2.||Activities of Daily Living (ADL)
|3.||Home Nursing (Nursing, Home)
|5.||Drug Therapy (Chemotherapy)